financetom
Business
financetom
/
Business
/
Tesla, shareholder clash over $7-billion legal fee request in Musk pay case
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla, shareholder clash over $7-billion legal fee request in Musk pay case
Jul 8, 2024 11:33 AM

WILMINGTON, Delaware, July 8 (Reuters) - Legal teams for

Tesla and a shareholder clashed in court on Monday over the

value of a lawsuit that successfully challenged CEO Elon Musk's

enormous pay package and a request for the company to pay a

record legal fee worth $7 billion.

For more than three hours, two experts offered opposing

testimony about the benefit created for Tesla by a

Delaware judge's January ruling that rescinded Musk's

$56-billion pay package.

The legal fee is being pursued by Richard Tornetta, who

owned nine shares of Tesla when he sued over Musk's pay package

in 2018. It equals around $7.3 billion at Tesla's Monday stock

price and amounts to a rate of roughly $370,000 for every hour

worked by the 37 lawyers, associates and paralegals, some of

whom normally bill as little as $275 an hour, according to court

documents submitted by Tornetta's lawyers.

Three law firms represented Tornetta, including Bernstein

Litowitz Berger & Grossmann.

Tornetta's lawyers argue they deserve the fee as a cut of

the benefit they say they conveyed to Tesla when Chancellor

Kathaleen McCormick voided Musk's pay package, which returned to

Tesla around 266 million shares reserved for the stock options.

Robert Jackson, a former commissioner at the Securities and

Exchange Commission, testified in Delaware's Court of Chancery

on Monday that the ruling was worth $51 billion in the form of

returned stock to Tesla that had been reserved for Musk's

options.

Daniel Fischel, a University of Chicago law professor,

countered that there was no cost in cash to Tesla if Musk

exercised the grant of stock options.

"The rescission of the grant did not save Tesla one dollar,"

said Fischel.

He said awarding billions in attorneys' fees as a result

would be an "unjustified windfall."

The hearing will continue into the afternoon.

More than 8,000 Tesla stockholders have flooded the court

with some 1,500 letters and objections over the fee, according

to court documents.

Tornetta's attorneys said the January award was the largest

judgment ever awarded by an American court, excluding punitive

damages. They argued they should receive a fee equal to 11% of

that judgment, a percentage that is arguably conservative by

Delaware legal precedent. They asked to be paid in the form of

29 million Tesla shares.

RECORD FEE REQUEST

The fee request vastly outstrips the current record fee in

shareholder litigation of $688 million in an Enron class action,

according to Stanford Law School.

The Musk case took a dramatic turn when Tesla shareholders

in June voted to ratify Musk's pay, which Tesla has argued

corrected the flaws in the 2018 process that McCormick

identified in her ruling.

McCormick will hear arguments about the legal impact of the

ratification vote in the coming weeks.

The company argues that Musk's pay package has been restored

and that Tornetta's legal victory has been transformed into a

loss. As a result, the case conveyed no benefit to Tesla and the

shareholder lawyers should receive as little as $13.6 million,

Tesla said.

McCormick may take weeks or months to rule on the legal fee.

The Delaware Supreme Court is currently considering a $267

million fee request in a shareholder class action involving Dell

Technologies and that decision could provide fee guidance.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
iHeartMedia, National Football League Extend NFL Podcast Network Collaboration
iHeartMedia, National Football League Extend NFL Podcast Network Collaboration
Jan 8, 2025
10:46 AM EST, 01/08/2025 (MT Newswires) -- iHeartMedia (IHRT) and the National Football League extended their multi-year NFL Podcast Network collaboration, the companies said Wednesday. Financial terms were not disclosed. Under the terms, new original podcasts and NFL Club shows will debut every year, while iHeart will also look for other current podcasts to join the NFL Podcast Network, the...
GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says
GSK, Pfizer's RSV Vaccines to Warn of Neurological Disorder Risk, FDA Says
Jan 8, 2025
10:48 AM EST, 01/08/2025 (MT Newswires) -- GSK (GSK) and Pfizer's ( PFE ) respiratory syncytial virus vaccines will carry warnings of increased risk of Guillain-Barre Syndrome, the US Food and Drug Administration said Tuesday on its website. Results from a post-marketing observational study suggested an increased risk of Guillain-Barre Syndrome (GBS) during the 42 days after vaccination with Pfizer's...
Oracle Says Textura Processed Over $1 Trillion in Construction Payments
Oracle Says Textura Processed Over $1 Trillion in Construction Payments
Jan 8, 2025
10:51 AM EST, 01/08/2025 (MT Newswires) -- Oracle (ORCL) said Wednesday its Oracle Textura Payment Management Cloud Service had processed more than $1 trillion in construction payments to subcontractors. Launched in 2006, the cloud payment management system helps construction companies accelerate payments, mitigate risk, and enhance productivity and cash flow, Oracle said. Price: 162.22, Change: +0.19, Percent Change: +0.11 ...
Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment
Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment
Jan 8, 2025
10:51 AM EST, 01/08/2025 (MT Newswires) -- Denali Therapeutics ( DNLI ) said Wednesday the US Food and Drug Administration has given breakthrough therapy designation for tividenofusp alfa to treat people with Hunter syndrome, a rare genetic disease. The designation was created to quicken the development and review of candidate drugs to treat serious or life-threatening diseases, the company said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved